Press release


如何引用文章

全文:

详细

Perjeta™ (pertuzumab) in combination with Herceptin® (trastuzumab) and docetaxel increases in life expectancy of patients with HER2-positive metastatic breast cancer (mBC) by 15,7 months compared with standard regimen Herceptin/docetaxel. The data from the phase III CLEOPATRA study.

作者简介

- -

参考

  1. Swain S et al. Final overall survival (OS) analysis from the CLEOPATRA study of first - line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology 2014. Abstr. 350O_PR.
  2. F. Hoffmann-La Roche. ClinicalTrials.gov NCT00567190. National Library of Medicine; http://clinicaltrials.gov/ct2/show/NCT00567190
  3. Swain S et al. Confirmatory overall survival analysis of CLEOPATRA: A randomized, double - blind, placebo - controlled Phase III study with pertuzumab, trastuzumab, and docetaxel in patients with HER2-positive first - line metastatic breast cancer. Poster presentation at the 2012 CTRC- AACR San Antonio Breast Cancer Symposium. Abstr. P5-18-26.
  4. Wolff A.C et al. Arch Pathol Lab Med 2007; 131: 18-34.
  5. Dawood S et al. J Clin Oncol 2010; 28: 92.

版权所有 © Consilium Medicum, 2014

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##